University of California Berkeley-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of California Berkeley - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013338
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of California Berkeley (UC Berkeley), a subsidiary of University of California is an educational university that offers educational programs and research services. The university’s academic programs comprise law and economics program, legal studies; lesbian, gay, bisexual, and transgender studies, letters and science, liberal arts, linguistics, logic and the methodology of sciencebiophysics, biostatistics, buddhist studies, cognitive science, development practice, integrative biology, interdisciplinary studies, Jewish studies program, mathematics, and others. It carries out research in partnership with academic departments, institutes and centers, museums, and field stations. The university provides educational services through its colleges and schools. UC Berkeley is headquartered in Berkeley, California, the US.

University of California Berkeley – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
University of California Berkeley, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
University of California Berkeley, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
University of California Berkeley, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
University of California Berkeley, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
University of California Berkeley, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
University of California Berkeley, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Novartis Enters into Agreement with University of California 10
University of California, Berkeley Enters into Agreement with Aduro Biotech 11
University Of California Announces Co-Development Agreement With Harvard University 12
Licensing Agreements 13
Excision BioTherapeutics Enters into Licensing Agreement with University of California Berkeley 13
Aduro BioTech Enters into Licensing Agreement with UCB 14
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 15
Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 16
Avalanche Biotechnologies Enters Into Licensing Agreement With University of California, Berkeley 17
University of California Berkeley – Key Competitors 18
University of California Berkeley – Key Employees 19
University of California Berkeley – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Government and Public Interest 21
Nov 06, 2017: Scientists discover potential treatment to stop glaucoma in its tracks 21
Jul 19, 2017: UC Berkeley: Defense department pours $65 million into making CRISPR safer 23
Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 25
Jul 12, 2017: Anti-CRISPR proteins decrease off-target side effects of CRISPR-Cas9 28
Jan 13, 2017: Scientists reprogram embryonic stem cells to expand their potential cell fates 30
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 32
Jul 26, 2016: With Rise of Leukemia in Children, $6 Million Grant Funds Search for Causes 34
Mar 02, 2016: PET scans reveal key details of Alzheimer’s protein growth in aging brains 36
Jan 25, 2016: Crouching Protein, Hidden Enzyme : The Scripps Research Institute 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
University of California Berkeley, Pharmaceuticals & Healthcare, Key Facts 2
University of California Berkeley, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
University of California Berkeley, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
University of California Berkeley, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
University of California Berkeley, Deals By Therapy Area, 2011 to YTD 2017 8
University of California Berkeley, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novartis Enters into Agreement with University of California 10
University of California, Berkeley Enters into Agreement with Aduro Biotech 11
University Of California Announces Co-Development Agreement With Harvard University 12
Excision BioTherapeutics Enters into Licensing Agreement with University of California Berkeley 13
Aduro BioTech Enters into Licensing Agreement with UCB 14
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 15
Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 16
Avalanche Biotechnologies Enters Into Licensing Agreement With University of California, Berkeley 17
University of California Berkeley, Key Competitors 18
University of California Berkeley, Key Employees 19
University of California Berkeley, Subsidiaries 20

★海外企業調査レポート[University of California Berkeley-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Helm AG:企業の戦略・SWOT・財務情報
    Helm AG - Strategy, SWOT and Corporate Finance Report Summary Helm AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • SSA Marine, Inc.:企業の戦略・SWOT・財務分析
    SSA Marine, Inc. - Strategy, SWOT and Corporate Finance Report Summary SSA Marine, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ferring International Center SA-製薬・医療分野:企業M&A・提携分析
    Summary Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (foll …
  • Ajinomoto Co., Inc.:企業の戦略・SWOT・財務分析
    Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Ajinomoto Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Esprit Holdings Limited:企業の戦略・SWOT・財務分析
    Esprit Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Esprit Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • CNA Financial Corporation:企業の戦略・SWOT・財務情報
    CNA Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary CNA Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The Allstate Corp:企業の戦略・SWOT・財務情報
    The Allstate Corp - Strategy, SWOT and Corporate Finance Report Summary The Allstate Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Global Alliance for TB Drug Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis. The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers …
  • Grupo TMM, S.A.B. (TMMA):企業の財務・戦略的SWOT分析
    Grupo TMM, S.A.B. (TMMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • John Keells Hotels Plc
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hanmi Pharmaceuticals Co Ltd (128940):製薬・医療:M&Aディール及び事業提携情報
    Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counte …
  • Swift Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company’s products include 2S hyb DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • Lagardere Travel Retail S.A.S:企業の戦略・SWOT・財務情報
    Lagardere Travel Retail S.A.S - Strategy, SWOT and Corporate Finance Report Summary Lagardere Travel Retail S.A.S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Petroleo Brasileiro SA:企業の戦略・SWOT・財務分析
    Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report Summary Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Paladin Energy Ltd.:企業の戦略的SWOT分析
    Paladin Energy Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • FANUC CORPORATION:企業の戦略・SWOT・財務分析
    FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report Summary FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Athersys Inc (ATHX):製薬・医療:M&Aディール及び事業提携情報
    Summary Athersys Inc (Athersys) is a biotechnology company that discovers and develops of novel and proprietary best-in-class therapies in the field of regenerative medicine. Its lead platform, MultiStem, is a patented stem cell product, developed for treating multiple disease indications such as ca …
  • CellProthera-製薬・医療分野:企業M&A・提携分析
    Summary CellProthera (CellProthera) focuses on the development of therapeutic solutions for the regeneration of organs which are damaged by disease or trauma from autologous blood peripheral stem cells. The company’s lead candidate ProtheraCytes, is an advanced therapy medicinal product within tissu …
  • Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析
    Summary Erytech Pharma SA (ERYTECH Pharma) is a clinical-stage biopharmaceutical company developing red blood cell-based therapeutics for cancer and orphan diseases. Its pipeline product candidates include erymethionase (methionine-?-lyase), a novel amino acid agent targeting cancer metabolism in so …
  • Philogen SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Philogen SpA (Philogen) is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company provides pipeline products such as darleukin, teleukin, fibromun, radretumab, dekavil and tetravil, among others. It offers technologies such a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆